Azilsartan Medoxomil: A New Angiotensin Receptor Blocker

Zaiken, Kathy; Cheng, Judy

doi:10.1016/j.clinthera.2011.10.007

Cited by 59 publications

(42 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whereas Azilsartan 40 mg has comparable efficacy as olmesartan 40 mg. [12] Azilsartan (40mg and 80mg) showed significantly greater reduction in mean systolic blood pressure as compared to angiotensin converting enzyme inhibitor rampril 10mg daily [10] and also valsartan 320 mg. [13] Pleiotropic effects In addition to blood pressure lowering effect azilsartan has shown pleiotropic beneficial effects on cellular mechanisms of cardiometabolic disease in studies on experimental animals. [14] In a study on homogenates of the pooled aortas of ApoE knockout mice, azilsartan attenuated the evolution of atherosclerotic plaque rupture by suppressing Plasminogen activator inhibitor type-I (PAI-1).…”

Section: Results Of Clinical Studiesmentioning

confidence: 99%

“…[9] Other adverse effects include dizziness, diarrhea, nausea, asthenia, fatigue, muscle spasm and cough. [10,11] In patients more than 75 years of age or with moderate to severe renal impairment at baseline a small increase in serum creatinine levels is reported with azilsartan which is reversible on discontinuing the drug. [9] Like other Angiotensin receptor blockers, azilsartan is contraindicated during pregnancy as it can cause fetal injury and even death during the second or third trimester.…”

Section: Adverse Effects and Contraindicationsmentioning

confidence: 99%

See 1 more Smart Citation

Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

Sood¹,

Bajaj²

2018

IJMDS

View full text Add to dashboard Cite

show abstract

Section: Results Of Clinical Studiesmentioning

confidence: 99%

Section: Adverse Effects and Contraindicationsmentioning

confidence: 99%

Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

Sood¹,

Bajaj²

2018

IJMDS

View full text Add to dashboard Cite

show abstract

“…31 The result regarding the binding affinity of azilsartan and candesartan demonstrated that these ARBs interact with the same sites in the AT1 receptor [(Tyr (113), Lys (199), and Gln (257)] The hydrogen bonding between the oxadiazole of azilsartan-Gln (257) is stronger than that between the tetrazole of candesartan-Gln (257). 32,33 An examination of the inhibition of inositol phosphate (IP) production by ARBs using contitutively active mutant receptors indicated that inverse agonist activity required azilsartanGln (257) interaction and that azilsartan had a stronger activation with Gln (257) than candesartan. There was no difference among treatment groups in the incidence of clinical and laboratory adverse events.…”

Section: Discussionmentioning

confidence: 99%

Comparative study of efficacy and adverse effects profile of azilsartan, olmesartan and candesartan in the control of essential hypertension

Zaman¹,

Sinha²

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

INTRODUCTIONHypertension is a common disorder in adults around the globe and among the most common attributable causes of mortality.1 The goal of antihypertensive therapy is to maintain blood pressure of <140/90mmHg for most people. [2][3][4][5][6][7] The angiotensin receptor blockers (ARBs) have been in clinical use since 1995 and known to be effective antihypertensive agent with excellent tolerability profiles. Azilsartan medoximil, a new generation ARB for the treatment of essential hypertension. Azilsartan was discovered through the efforts of scientists from Takeda, a Japanese pharmaceutical company by modifying the tetrazole ring present in candesartan. The chemical structure of azilsartan is very similar to the structure of candesartan and differs only by replacement of candesartan's 5 member tetrazole ring with the oxaoxadiazole ring of azilsartan. This modification makes azilsartan less acidic and more lipophilic than candesartan. Azilsartan was recently approved and has been shown to provide a more potent and sustained antihypertensive effects than other ARBs. Azilsartan medoxomil, ABSTRACT Background: Hypertension has been identified as the leading risk factor for mortality worldwide. It may lead to damage of heart, kidney, brain, vasculature and the other organs results in premature morbidity and death. The angiotensin receptor blockers are effective antihypertensive agent with excellent tolerability profiles. Azilsartan medoximil is a new ARB recently approved for treatment of hypertension. The objective of the study was to compare efficacy and tolerability of once daily treatment of the new angiotensin type1 receptor blocker (ARB) Azilsartan with Olmesartan and Candesartan. Methods: The study was a prospective, randomized open label comparison. Total 411 patients were recruited for the study. Patients were divided into four groups. Group A comprising of 105 patients received azilsartan (40mg), Group B comprising of 106 patients received azilsartan (80mg), Group C comprising of 102 patients received olmesartan (40mg) and Group D comprising of 98 patients received candesartan (12mg). Blood pressure was monitored at base line, after 2 weeks, 4 weeks and 8 weeks of treatment. Results: All groups were well matched in terms of age, weight, clinical findings and laboratory values. All drugs reduced both systolic blood pressure (SBP) and Diastolic blood pressure (DSP) significantly, but the reduction in SBP and DSP with azilsartan (80mg) was significantly greater than other drugs. The difference in BP reduction between azilsartan (40mg) and olmesartan (40mg) were not significant but both azilsartan (40mg) and olmesartan (40mg) were significantly more effective than candesartan(12mg). Conclusions: The study indicates that azilsartan (80mg) is more effective in the control of hypertension than olmesartan and candesartan with similar safety profile.

show abstract

“…It has been proposed that azilsartan due to its pharmacological and pharmacodynamic properties is more potent and powerful in comparison to other ARBs given in comparable doses. 4,5 For example, studies have demonstrated that azilsartan induces greater reductions in blood pressure compared to olmesartan which is considered as the most effective among the ARBs. 6,7 It appears that azilsartan is more effective than olmesartan and valsartan in the treatment of hypertension.…”

Section: Azilsartan-a New Generation Arbmentioning

confidence: 99%

Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol

Sharma¹

2015

Hypertension Journal

View full text Add to dashboard Cite

Uncontrolled hypertension is the major risk factor for cardio vascular disease. The economic burden of disease is enor mous in developed as well as in developing countries. The epidemiological studies have explained many etiological factors associated with chronic untreated hypertension, which varies according to geography and ethnicity.In last five decades, many classes and types of antihyper tensive drugs have been developed. This pharma cological review provides an update on new molecules belonging to three pharmacological classes of antihypertensives-angiotensin receptor blocker (azilsartan), calcium channel blocker (cilnidipine) and beta blocker (nebivolol) and their clinical implications.

show abstract

Azilsartan Medoxomil: A New Angiotensin Receptor Blocker

Cited by 59 publications

References 12 publications

Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

Comparative study of efficacy and adverse effects profile of azilsartan, olmesartan and candesartan in the control of essential hypertension

Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol

Contact Info

Product

Resources

About